Posts

Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

F2G and Shionogi Report Positive Phase 3 Results for Oral Antifungal Olorofim in Invasive Aspergillosis

on

UniQure stock surges after FDA U-turn clears path to gene therapy filing

on

Takeda's AI‑designed psoriasis pill beats Bristol Myers Squibb's Sotyktu in Phase 3 head‑to‑head trial

on

J&J's Ottava Surgical Robot Meets Primary Endpoints in Gastric Bypass Study

on

Corcept's Phase 2 DAZALS Study Shows Dazucorilant Provides 87% Reduction in Mortality Risk Over Two Years in ALS Patients

on

Small Pools, Big Ideas: How the Rare Disease Community is Reimagining Clinical Trials

on

Insmed's Arikayce Achieves Phase 3 Success in MAC Lung Disease, Paving Way for Label Expansion and Potential Blockbuster Status

on

Pfizer and Valneva's Lyme Vaccine Misses Primary Endpoint But Pursue Regulatory Approval

on

Kainova Therapeutics Announces Positive Phase I Results for DT-9081 in Advanced Solid Tumors

on

Ocular Therapeutix's Axpaxli Demonstrates Superiority Over Regeneron's Eylea in Phase 3 Trial for Wet AMD

on

The Lancet Publishes TRICORDER Study: AI-Enabled Stethoscopes Boost Cardiac Detection in NHS Trial

on

Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer

on

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

on

Roche Bags EU Nod for SC Formulation of Lunsumio, Re-Igniting Bispecific Battle with Tepkinly

on

FDA Unveils Long-Awaited Biosimilar Guidance to Accelerate Approvals and Cut Costs

on

Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results

on

Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial

on

Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial

on